Company:Editas Medicine

From HandWiki
Revision as of 17:14, 9 February 2024 by Corlink (talk | contribs) (fix)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Discovery-phase pharmaceutical company
Editas Medicine, Inc.
TypePublic
Industry
FoundedNovember 2013; 11 years ago (2013-11) in Cambridge, Massachusetts
Founders
Headquarters
Cambridge, Massachusetts
,
United States
Number of locations
2
Key people
  • James Mullen (Chairman)
  • Gilmore O'Neill (President and CEO)
RevenueDecrease US$19.7 million (2022)
Decrease US$−226 million (2022)
Decrease US$−220 million (2022)
Total assetsDecrease US$514 million (2022)
Total equityDecrease US$361 million (2022)
Number of employees
226 (2023)
Websiteeditasmedicine.com
Footnotes / references
[1]

Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology.[2][3] Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.[4][5][6]

History

Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley,[7] and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures; the name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.[8][9][10]

In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors.[11][12] it went public on 2 February 2016,[2] via an initial public offering that raised $94 million.[13][14]

The company entered into a strategic collaboration with Juno Therapeutics in 2015 to combine its CRISPR-Cas9 technology with Juno's experience in creating chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics.[15] Juno was later acquired by Celgene,[16] which was in turn acquired by Bristol Myers Squibb.[17]

The company announced in 2015 that it was planning a clinical trial in 2017 using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness.[18][10] On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587).[19][20] In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.[21]

In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions.[22][23] Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.[24]

In 2019, the company was building new chemistry facilities in Boulder, Colorado.[5]

Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins.[25][26] Collins was replaced in 2021 by James Mullen, who had been board chairman.[27] Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.[28]

Research

Editas works with two different CRISPR nucleases, Cas9 and Cas12a.[29]

EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, which is currently in clinical trials.

EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;.[30][31] In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.[32]

References

  1. ↑ "2022 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 22, 2023. https://www.sec.gov/Archives/edgar/data/1650664/000155837023001764/edit-20221231x10k.htm. 
  2. ↑ 2.0 2.1 "The week in science: 5–11 February 2016". Nature 530 (7589): Business: CRISPR goes public. 10 Feb 2016. doi:10.1038/530134a. Bibcode: 2016Natur.530..134.. open access
  3. ↑ "Editas Wins FDA Approval for IND of CRISPR Treatment for LCA10". Genetic Engineering & Biotechnology News. 30 November 2018. https://www.genengnews.com/news/editas-wins-fda-approval-for-ind-of-crispr-treatment-for-lca10/. 
  4. ↑ Werley, Jensen (5 September 2019). "How Boulder biotech companies are putting Colorado on the gene-editing map". American City Business Journals. https://www.bizjournals.com/denver/news/2019/09/05/boulder-colorado-biotech-gene-editing.html. 
  5. ↑ 5.0 5.1 Symington, Steve (20 August 2020). "Editas Medicine Remains on Track". The Motley Fool. https://www.fool.com/investing/2019/08/06/editas-medicine-remains-on-track.aspx. 
  6. ↑ "Who We Are" (in en-US). https://www.editasmedicine.com/about/. 
  7. ↑ Rockoff, Jonathan (2015-06-29). "Why Gene-Editing Technology Has Scientists Excited" (in en-US). Wall Street Journal. ISSN 0099-9660. https://www.wsj.com/articles/why-gene-editing-technology-has-scientists-excited-1434985998. 
  8. ↑ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 209–212. ISBN 978-1-9821-1585-2. 
  9. ↑ John Carroll (Nov 25, 2013). "Biotech pioneer in 'gene editing' launches with $43M in VC cash". FierceBiotech. https://www.fiercebiotech.com/r-d/biotech-pioneer-gene-editing-launches-43m-vc-cash. 
  10. ↑ 10.0 10.1 Regalado, Antonio (2015-11-05). "CRISPR Gene Editing to Be Tested on People by 2017, Says Editas". https://www.technologyreview.com/s/543181/crispr-gene-editing-to-be-tested-on-people-by-2017-says-editas/. 
  11. ↑ Nowogrodzki, Anna (10 August 2015). "Gene-Editing Startup Raises $120 Million to Apply CRISPR to Medicine". MIT Technology Review. https://www.technologyreview.com/2015/08/10/110076/gene-editing-startup-raises-120-million-to-apply-crispr-to-medicine/. 
  12. ↑ Loria, Kevin (12 April 2018). "Bill Gates says it would be a 'tragedy' to pass up a controversial, revolutionary gene-editing technology". Business Insider. https://www.businessinsider.com/bill-gates-pushing-genetic-editing-with-crispr-2018-4. 
  13. ↑ Pflanzer, Lydia (2 February 2016). "A Bill Gates-backed startup that wants to edit your genes just raised nearly $100 million". Business Insider. https://www.businessinsider.com/editas-ipo-raises-944-million-2016-2. 
  14. ↑ Fidler, Ben (2 February 2016). "CRISPR Hits Wall Street as Editas Bags $94M in IPO". Xconomy. https://xconomy.com/boston/2016/02/02/crispr-hits-wall-street-as-editas-bags-94m-in-ipo/. 
  15. ↑ "Juno, Editas Launch Up-to-$737M+ Cancer Therapy Collaboration". Genetic Engineering & Biotechnology News. 27 May 2015. http://www.genengnews.com/gen-news-highlights/juno-editas-launch-up-to-737m-cancer-therapy-collaboration/81251315/. Retrieved 2016-02-11. open access
  16. ↑ Lombardo, Cara (2018-01-22). "Celgene to Buy Juno Therapeutics for $9 Billion" (in en-US). Wall Street Journal. ISSN 0099-9660. https://www.wsj.com/articles/celgene-to-buy-juno-therapeutics-for-9-billion-1516624153. 
  17. ↑ Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company, PM BMS, November 20, 2019; retrieved May 20, 2020
  18. ↑ Kuchler, Hannah (6 January 2020). "Crispr puts first human in-body gene editing to test". Financial Times. https://www.ft.com/content/0fbf0604-1df5-11ea-97df-cc63de1d73f4. 
  19. ↑ "First CRISPR therapy dosed". Nature 38 (4): 382. 7 April 2020. doi:10.1038/s41587-020-0493-4. PMID 32265555. 
  20. ↑ Sheridan, Cormac (14 December 2018). "Go-ahead for first in-body CRISPR medicine testing". Nature. doi:10.1038/d41587-018-00003-2. https://www.nature.com/articles/d41587-018-00003-2. Retrieved 21 December 2018. 
  21. ↑ "Editas Medicine Announces Positive Initial Clinical Data From Ongoing Phase 1/2 BRILLIANCE Clinical Trial Of EDIT-101 For LCA10". 29 September 2021. https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-positive-initial-clinical-data-ongoing. 
  22. ↑ Stein, Rob (4 March 2020). "In A 1st, Scientists Use Revolutionary Gene-Editing Tool To Edit Inside A Patient". NPR. https://www.npr.org/sections/health-shots/2020/03/04/811461486/in-a-1st-scientists-use-revolutionary-gene-editing-tool-to-edit-inside-a-patient. 
  23. ↑ Terry, Mark (4 March 2020). "Allergan and Editas Dose First Patient in Historic CRISPR Trial for Inherited Blindness". BioSpace. https://www.biospace.com/article/allergan-and-editas-dose-1st-patient-in-crispr-trial/. 
  24. ↑ Fidler, Ben (7 August 2020). "Editas, AbbVie rework gene editing deal as pioneering CRISPR trial resumes". BioPharma Dive. https://www.biopharmadive.com/news/editas-abbvie-end-crispr-gene-editing-deal/583118/. 
  25. ↑ Dearment, Alaric (22 January 2019). "Editas Medicine CEO steps down as company moves into product development stage". MedCity News. https://medcitynews.com/2019/01/editas-medicine-ceo-steps-down-as-company-moves-into-product-development-stage/. 
  26. ↑ DeAngelis, Allison (6 August 2019). "Editas became Cindy Collins. CEO". Boston Business Journal. https://www.bizjournals.com/boston/news/2019/08/06/editas-picks-cindy-collins-as-permanent-chief.html. 
  27. ↑ "Editas Medicine Announces Appointment Of James C. Mullen As Chief Executive Officer" (Press release). Editas Medicine. 8 February 2021.
  28. ↑ Keown, Alex (14 April 2022). "Gilmore O'Neill "Excited" to Take the Reins at Editas Medicine". BioSpace. https://www.biospace.com/article/gilmore-o-neill-excited-to-take-the-reins-at-editas-medicine-. 
  29. ↑ Pickar-Oliver, Adrian; Gersbach, Charles A. (August 2019). "The next generation of CRISPR–Cas technologies and applications" (in en). Nature Reviews Molecular Cell Biology 20 (8): 490–507. doi:10.1038/s41580-019-0131-5. ISSN 1471-0080. PMID 31147612. 
  30. ↑ Rees, Victoria (20 June 2019). "Experimental treatment for sickle cell disease success". Drug Target Review. https://www.drugtargetreview.com/news/45322/experimental-treatment-for-sickle-cell-disease-success/. 
  31. ↑ Wong, Sandi (10 December 2019). "Editas shows better gene editing using Cas9 alternative for sickle cell, thalassemia". BioCentury. https://www.biocentury.com/article/304012/editas-preclinical-data-suggest-cas12a-better-than-cas9-for-edited-cell-therapy-for-sickle-cell-thalassemia. 
  32. ↑ Carvalho, Joana. "FDA Clears Way for Trial of Gene Editing Therapy for Severe SCD" (in en-US). https://sicklecellanemianews.com/2021/01/21/fda-clears-way-edit-301-gene-editing-cell-therapy-to-enter-clinical-testing-severe-scd/. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Editas_Medicine&oldid=3474879"